The US Food and Drug Administration has granted AstraZeneca’s (LSE: AZN) Calquence (acalabrutinib) full approval as part of a combination therapy for mantle cell lymphoma (MCL).
The nod covers the first-line treatment of adults who are ineligible for autologous hematopoietic stem cell transplantation. Calquence also received full approval as a monotherapy for previously treated MCL, converting its 2017 accelerated approval into a traditional one.
The decision was supported by data from the Phase III ECHO trial, which showed a 27% lower risk of disease progression or death, and a median progression-free survival (PFS) of 66.4 months, compared to 49.6 months in the comparator group.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze